# A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.

> **NCT05493995** · PHASE2 · COMPLETED · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 66 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Penpulimab
- **DRUG:** Anlotinib
- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT05493995
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-21
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2024-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05493995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05493995, "A Study of Penpulimab and Anlotinib Plus Nab-paclitaxel and Gemcitabine for Metastatic Pancreatic Cancer.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05493995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*